Euformatics, ViennaLab, Oncompass win European liquid biopsy development contract (Genomeweb)
"Finnish NGS data firm Euformatics and partners ViennaLab Diagnostics and Oncompass Medicine have been awarded a Phase 1 contract by a group of leading European hospitals to research and develop an economically sustainable liquid biopsy platform for molecular profiling in cancer patients, Euformatics said on Monday...The group's project is one of four collectively funded by the OncNGS program's €7 million. The other three contractors are Belgian university KU Leuven, Agilent Technologies Belgium, and OncoDNA."